PSMA靶向放射配体治疗与镭-223在前列腺癌骨转移中的应用
本文综述了骨转移在前列腺癌中的治疗生物学异质性,整合了ALSYMPCA、ERA-223、PEACE-3、VISION、TheraP、PSMAfore、RALU和AlphaBet等研究,指出镭-223有随机生存获益证据,而PSMA靶向放射配体治疗可靶向PSMA表达病灶,两者机制互补但互补定位不等同临床协同。RALU报告133例回顾性安全性结局,AlphaBet报告单臂早期安全性及抗肿瘤活性,均无随机增量生存获益证据;PEACE-3证实镭-223联合恩扎卢胺在现代骨保护实践下总生存获益,ERA-223则提示不当联合的骨折风险。
要点
- 镭-223在特定mCRPC男性中有随机总生存获益证据。
- PSMA靶向放射配体治疗向PSMA表达骨和软组织病灶递送辐射。
- 双核素联合的增量生存获益尚无随机证据,应限制于受控试验。
核心结论
- 最可辩护的临床策略是根据疾病分布和治疗史,以证据权重选择核素治疗。
- 同步双核素方法应限制在适当监管的临床试验中。
研究设计与样本
- 本综述批判性整合了ALSYMPCA、ERA-223、PEACE-3、VISION、TheraP、PSMAfore、RALU和AlphaBet等研究。
- RALU报告为133例回顾性报告,描述镥-177-PSMA序贯镭-223后的安全性和结局。
- AlphaBet报告为单臂早期研究,报告镥-177-PSMA-I&T同步镭-223的初步安全性和抗肿瘤活性。
主要发现
- 镭-223二氯化物是有随机总生存获益证据的骨靶向α发射体,适用于特定mCRPC男性。
- PSMA靶向放射配体治疗向PSMA表达肿瘤沉积递送辐射,包括骨和软组织。
- RALU和AlphaBet均未提供双核素治疗增量生存获益的随机证据。
- PEACE-3证实镭-223联合恩扎卢胺在现代骨保护实践下总生存获益。
- ERA-223强调不当联合的骨折风险。
关键数值与推荐
- 镭-223在特定mCRPC男性中有随机总生存获益证据。
- PEACE-3确立镭-223联合恩扎卢胺的总生存获益。
- ERA-223提示不当联合的骨折风险。
临床怎么用
- 根据疾病分布和治疗史,以证据权重选择核素治疗。
- 同步双核素方法应限制在适当监管的临床试验中。
- 未来试验需整合病灶级成像、全身疾病表型、骨髓储备、患者报告结局、竞争性全身治疗和个体化辐射暴露。
局限性
- RALU为回顾性报告,AlphaBet为单臂早期研究,均非随机对照。
- 互补定位本身不能确立临床协同作用。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Bone metastases are a major cause of pain, skeletal complications, marrow compromise and mortality in advanced prostate cancer. The therapeutic biology of skeletal disease is heterogeneous: malignant epithelial cells expressing prostate-specific membrane antigen (PSMA) coexist with osteoblasts, osteoclasts, reactive mineralising bone and variable marrow infiltration. Radium-223 dichloride is a bone-seeking alpha emitter with randomised evidence of overall-survival benefit in selected men with metastatic castration-resistant prostate cancer (mCRPC), whereas PSMA-targeted radioligand therapy delivers radiation to PSMA-expressing tumour deposits in bone and soft tissues. Their mechanistic complementarity has motivated sequential and concurrent strategies, but complementary localisation does not itself establish clinical synergy. This review critically integrates ALSYMPCA, ERA-223, PEACE-3, VISION, TheraP, PSMAfore, RALU and AlphaBet, together with radiobiology, molecular imaging, marrow and skeletal toxicity, dosimetry and evolving therapeutic sequencing. The final 133-patient retrospective RALU report describes the safety and outcomes observed after radium-223 followed by lutetium-177-PSMA in selected heavily pretreated patients; AlphaBet reports preliminary safety and antitumour activity with concurrent lutetium-177-PSMA-I&T and radium-223 in a single-arm early-phase study. Neither provides randomised evidence of an incremental survival benefit for dual-radionuclide treatment. Conversely, PEACE-3 establishes an overall-survival benefit for radium-223 combined with enzalutamide under contemporary bone-protective practice, whereas ERA-223 underscores the fracture hazards of inappropriate combinations. Future trials must integrate lesion-level imaging, whole-body disease phenotype, marrow reserve, patient-reported outcomes, competing systemic treatments and personalised radiation exposure. The most defensible clinical strategy is evidence-weighted selection of radionuclide therapy according to disease distribution and treatment history, with concurrent dual-radionuclide approaches restricted to appropriately governed trials.
引用
- Sathekge. PSMA-directed radioligand therapy and radium-223 in prostate cancer bone metastases. Semin Nucl Med. 2026. PMID: 42951717. doi:10.1053/j.semnuclmed.2026.10.003
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。